
1 - 10 funcionários
Fundada em 2017
🏥 Saúde
🧬 Biotecnologia
💊 Farmacêutico
💰 $100.000.000 Private Equity Round em 2022-04
Healthcare • Biotechnology • Pharmaceuticals
Dianthus Therapeutics, Inc. é uma empresa de biotecnologia em estágio clínico focada no desenvolvimento de novos anticorpos monoclonais para tratar doenças autoimunes e inflamatórias graves. A companhia utiliza tecnologias avançadas de engenharia de anticorpos para criar terapias de próxima geração direcionadas ao sistema complemento, com seletividade e potência aprimoradas. Seu programa líder, o DNTH103, é um anticorpo monoclonal que tem como alvo a via clássica do sistema complemento para condições como miastenia gravis generalizada, neuropatia motora multifocal e polirradiculoneuropatia desmielinizante inflamatória crônica. Com sedes em Nova York e Waltham, Massachusetts, a Dianthus busca oferecer terapias transformadoras, atendendo necessidades médicas não atendidas no tratamento de doenças autoimunes.
🕒 Maio 26
🗣️🇺🇸🇬🇧 Inglês obrigatório
Melhore suas chances de conseguir uma entrevista verificando sua pontuação de currículo antes de se candidatar.

1 - 10 funcionários
Fundada em 2017
🏥 Saúde
🧬 Biotecnologia
💊 Farmacêutico
💰 $100.000.000 Private Equity Round em 2022-04
Healthcare • Biotechnology • Pharmaceuticals
Dianthus Therapeutics, Inc. é uma empresa de biotecnologia em estágio clínico focada no desenvolvimento de novos anticorpos monoclonais para tratar doenças autoimunes e inflamatórias graves. A companhia utiliza tecnologias avançadas de engenharia de anticorpos para criar terapias de próxima geração direcionadas ao sistema complemento, com seletividade e potência aprimoradas. Seu programa líder, o DNTH103, é um anticorpo monoclonal que tem como alvo a via clássica do sistema complemento para condições como miastenia gravis generalizada, neuropatia motora multifocal e polirradiculoneuropatia desmielinizante inflamatória crônica. Com sedes em Nova York e Waltham, Massachusetts, a Dianthus busca oferecer terapias transformadoras, atendendo necessidades médicas não atendidas no tratamento de doenças autoimunes.
• Lead formulation development strategy for a new bispecific fusion protein from preclinical stage through clinical development. • Design and execute studies to assess protein stability, aggregation, degradation pathways, viscosity, and developability under relevant formulation conditions. • Develop liquid and, where appropriate, lyophilized formulations to support both IV and SC presentations. • Lead excipient screening, buffer optimization, pH optimization, surfactant selection, and stress stability studies to identify robust drug product formulations. • Drive high-concentration formulation development for subcutaneous delivery, including syringeability, injectability, and device compatibility assessments. • Partner closely with Analytical Development to establish appropriate characterization methods for formulation screening, stability assessment, and comparability studies. • Collaborate with Drug Substance, Process Development, Quality, Regulatory, Clinical Supply, and external CDMOs to ensure alignment between formulation strategy, manufacturability, and clinical needs. • Provide technical leadership for drug product process development, fill-finish considerations, container closure selection, and tech transfer activities. • Serve as the formulation subject matter expert during regulatory interactions and contribute to CMC sections of regulatory filings, including IND, IMPD, and BLA submissions. • Identify formulation-related risks early and develop mitigation strategies to support program timelines and long-term product quality. • Evaluate and implement new technologies and platform approaches to improve formulation development capabilities for complex biologics.
• Ph.D. in Pharmaceutical Sciences, Chemistry, Chemical Engineering, Biochemistry, or a related field with 8+ years of relevant industry experience; or M.S. with 10+ years of relevant experience. • Deep expertise in formulation development for biologics, including monoclonal antibodies, bispecific antibodies, fusion proteins, or other large-molecule therapeutics. • Strong hands-on experience with protein stability assessment, excipient selection, buffer optimization, and formulation screening for early- and late-stage development. • Demonstrated experience developing formulations for high-concentration biologics and supporting subcutaneous and intravenous presentations. • Familiarity with key challenges associated with complex protein therapeutics, including aggregation, fragmentation, oxidation, deamidation, viscosity, and interfacial instability. • Experience working with external CDMOs and managing outsourced formulation and drug product development activities. • Strong understanding of drug product manufacturing, fill-finish operations, container closure systems, and clinical supply requirements. • Familiarity with regulatory expectations for formulation and drug product development in biologics programs. • Excellent leadership, communication, and project management skills, with the ability to work effectively across multidisciplinary teams. • Prior experience supporting regulatory submissions and health authority interactions is preferred.
• Flexible working arrangements • Professional development opportunities
Candidatar-se🕒 Maio 22
Senior Director, Construction overseeing construction activities to support company growth and operational excellence. Collaborating with cross-functional teams and providing leadership and strategic direction.
🗣️🇺🇸🇬🇧 Inglês obrigatório
🕒 Maio 22
Drive commercial strategy and program management for AI-powered HCP engagement. Seeking a seasoned leader to partner with the Chief Commercial Officer.
🇺🇸 Estados Unidos – Remoto (EUA)
💵 $170.000 - $220.000 / ano
💰 $3.000.000 Seed Round em 2022-04
⏰ Tempo Integral
🟠 Sênior
👔 Diretor
🗣️🇺🇸🇬🇧 Inglês obrigatório
🕒 Maio 22
Clinical data manager overseeing external data acquisition for clinical trials at Genmab. Ensuring high-quality data integration and leading external vendor oversight.
🇺🇸 Estados Unidos – Remoto (EUA)
💵 $157.360 - $236.040 / ano
💰 $134.000.000 Post-IPO Equity em 2010-06
⏰ Tempo Integral
🟠 Sênior
👔 Diretor
🦅 Patrocina Visto H1B
🗣️🇺🇸🇬🇧 Inglês obrigatório
🕒 Maio 22
Associate Director driving strategic insights and competitive intelligence for CSL Plasma. Leading analysis and recommendations to inform high-impact leadership decisions in the biopharmaceutical space.
🇺🇸 Estados Unidos – Remoto (EUA)
💰 $111.000.000 Post-IPO Equity em 2004-02
⏰ Tempo Integral
🟠 Sênior
👔 Diretor
🦅 Patrocina Visto H1B
🗣️🇺🇸🇬🇧 Inglês obrigatório
🕒 Maio 22
Senior Director of National Accounts at Neurotech Pharmaceuticals. Leading market access strategies and managing the Director of National Accounts team within the biotech industry.
🗣️🇺🇸🇬🇧 Inglês obrigatório